Aug. 3 at 5:58 PM
$OSRH The reason investors are watching VXM01 is not just the potential to treat one cancer — it’s the possibility that it becomes a repeatable cancer immunotherapy platform.
Early investors in companies like
$MRNA and
$BNTX were not only investing in a single product; they were investing in the idea that the underlying technology could create multiple medicines across large markets.
VXM01 is currently being explored in difficult-to-treat cancers like glioblastoma and pancreatic cancer, which together represent a potential
$6B–
$18B+ market opportunity.
The bigger upside is platform expansion. If VXM01 can work across additional solid tumors like lung, colorectal, kidney, liver, and ovarian cancers, this could move from a single-asset biotech into a broader oncology platform company.
The key question is not just: Can VXM01 treat one cancer?
It’s: Can VXM01 become a new way to fight multiple cancers?
That’s the type of platform potential that can create
$IGNIFICANT value.
